

# A facile synthesis of novel 1,7-dihydropyrazolo[3,4-*b*]pyridine-4,6-diones<sup>†</sup>

Dekai Yuan, Zhengming Li\*, and Weiguang Zhao

State Key Laboratory of Elemento-Organic Chemistry, Institute of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, P.R. China

1,7-Dihydropyrazolo[3,4-*b*]pyridine-4,6-diones **4** were obtained from ethyl 3-methylthio-5-aminopyrazole-4-carboxylate and diketene in three steps. A series of 5-anilinomethylene-1,7-dihydropyrazolo[3,4-*b*]pyridine-4,6-diones **5** was easily derived from **4**.

**Keywords:** fused pyrazoles, fused pyridines, diketene

Pyrazolo[3,4-*b*]pyridines have diverse biological activities in pharmacology and agrochemistry.<sup>1,2</sup> It has been reported that a pyrazolopyridine, BAY 41-2272, can stimulate guanylate cyclase by a mechanism independent of NO and offer an approach for treating cardiovascular diseases.<sup>3-5</sup> A tobacco company has found some compounds that could treat fibrosis effectively.<sup>6</sup> Other work has shown that they can also be used to treat diabetes<sup>7</sup> and malaria.<sup>8</sup> Furthermore, some derivatives have been found to have microbicidal<sup>9</sup> and herbicidal<sup>10</sup> activities in agrochemistry. Pyrazolo[3,4-*b*]pyridines are reported to be synthesised from 2-halo-3-carbonylpyridines or their derivatives with hydrazine hydrate,<sup>11</sup> or from 5-amino-4-cyanopyrazole with  $\beta$ -dicarbonyl compounds,<sup>12</sup> or from 5-aminopyrazoles with chalcones with long reaction times and in low yields.<sup>13</sup>


Heterocyclic rings containing the 1,3-dione structure have been discovered in many natural-products possessing biological activity,<sup>14,15</sup> and some 3-anilinomethylene-5,6-dihydro-6-(substituted phenyl)-2*H*-pyran-2,4-diones were found which possessed good fungicidal and plant growth regulation activity in our earlier work.<sup>16</sup> So several 5-anilinomethylenepyrazolo[3,4-*b*]pyridine-4,6-diones (**5**) were designed and obtained from 4-hydroxypyrazolo[3,4-*b*]pyridin-6-one (**4**) with triethyl orthoformate and substituted aniline. A novel three-step route to 4-hydroxy-1-phenyl-1,7-dihydropyrazolo[3,4-*b*]pyridin-6-one (**4**) was devised using ethyl 5-amino-3-methylthiopyrazole-4-carboxylate (**1**) and diketene as starting materials (Scheme 1).

Compound **1**, as a weak amine, does not react with diketene directly or when catalysed by Et<sub>3</sub>N, but in HOAc or catalysed by DMAP in CH<sub>2</sub>Cl<sub>2</sub>, it could be acetoacetylated by diketene and ethyl 5-acetoacetyl-amino-3-methylthio-1-phenyl-1*H*-pyrazole-4-carboxylate (**2**) was obtained in good yield. Then 5-acetyl-4-hydroxypyrazolo[3,4-*b*]pyridin-6-one (**3**) was prepared from **2** by Dieckmann cyclisation in refluxing EtONa/EtOH<sup>17</sup> in excellent yield. Treated with H<sub>2</sub>SO<sub>4</sub> and then ice-water, **3** was converted into 4-hydroxypyrazolo[3,4-*b*]pyridin-6-one **4**, again in good yield. The 5-anilinomethylene-1,7-dihydropyrazolo[3,4-*b*]pyridine-4,6-diones **5** were prepared in refluxing EtOH in a “one-pot” reaction of **4**, triethyl orthoformate and a substituted aniline.<sup>18</sup> The products **5** were found by <sup>1</sup>H NMR spectra to be composed of pairs of *Z* and *E* isomers containing intramolecular hydrogen bonds as earlier reported.<sup>18</sup>

Since 5-amino-1*H*-pyrazole-4-carboxylates **1** can be easily prepared from dithioacetals or *N,S*-acetals and hydrazines, pyrazolo[3,4-*b*]pyridine-4,6-diones with different substituents are readily obtainable under mild conditions by our method.

## Experimental

<sup>1</sup>H NMR spectra were obtained at 300MHz using a 300 Bruker AC 300F spectrometer. Because of poor solubility, some of the spectra were run at 70 °C. IR spectra were taken on an Equinox 55 IR spectrometer (KBr). Mass spectra were obtained using a VG ZAB-HS mass spectrometer (E.I. source). Elemental analyses were carried out



**Reagents:** **a:** diketene, HOAc; **b:** diketene, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; **c:** NaOEt, EtOH, reflux; **d:** H<sub>2</sub>SO<sub>4</sub> (90%); **e:** CH(OEt)<sub>3</sub>, aniline

**5a:** R = 4-Me, **5b:** R = 2-Cl; **5c:** R = 2-Br, **5d:** R = 2-Me

**Scheme 1** Synthesis of pyrazolo[3,4-*b*]pyridine-4,6-diones

\* To receive any correspondence. E-mail: yuandekai@eyou.com

<sup>†</sup> This is a Short Paper, there is therefore no corresponding material in *J. Chem. Research (M)*.

on a Yanaco CHN Corder MT-3 elemental analyzer. Melting points were taken using a Yanaco 500 melting-point apparatus.

*Ethyl 5-acetoacetyl-3-methylthio-1-phenyl-1H-pyrazole-4-carboxylate (2)* was prepared from pyrazole **1** with diketene in the following ways:

*Method a:* Pyrazole **1** (1.36 g, 0.005 mol) and diketene (0.55 g, 0.0072 mol) were dissolved in 5 ml HOAc and reacted at 80 °C for 10 h. The solvent was removed under reduced pressure and 20 ml water was added. After extraction with CH<sub>2</sub>Cl<sub>2</sub>, the organic layer was washed to neutral with saturated aqueous NaHCO<sub>3</sub> and dried with anhydrous MgSO<sub>4</sub> for 24 h. After the solvent was removed, **2** (1.4 g) was purified with reduced pressure chromatography (petroleum ether/ethyl acetate v/v 4:1) as white solid, m.p. 117–120 °C, yield 78 %; <sup>1</sup>H NMR δ (CDCl<sub>3</sub>, ppm): 1.36 (t, 3H, *J* = 7.1 Hz), 2.22 (s, 3H), 2.54 (s, 3H), 3.44 (s, 2H), 4.31 (q, 2H, *J* = 7.1 Hz), 7.41–7.46 (m, 5H); Anal. Calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub>S: C 56.50, H 5.26, N 11.63. Found: C 56.13, H 5.07, N 11.41 %.

*Method b:* **1** (1.36 g, 0.005 mol), diketene (0.55 g, 0.0072 mol) and DMAP (0.01 g) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 ml) at 0 °C, and then refluxed for 4 h. After the solvent was removed, **2** was obtained in a yield of 77 % after purification by reduced pressure chromatography.

*5-Acetyl-4-hydroxy-3-methylthio-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-b]pyridin-6-one (3):* Compound **2** (3.57 g, 0.01 mol) was dissolved in EtOH (30 ml) containing NaOEt (1.04 g, 0.02 mol) and refluxed for 4 h. During the reaction the sodium salt of **3** precipitated as a white solid. After the solvent was removed under reduced pressure, water (10 ml) was added to the residue and a colorless solution was formed. The solution was acidified to pH <3 with dilute HCl and **3** separated. After drying *in vacuo*, **3** was obtained as white needles, m.p. 270 °C(dec.), yield 96 %; <sup>1</sup>H NMR δ (CDCl<sub>3</sub>, ppm): 2.47 (s, 3H), 2.62 (s, 3H), 7.52 (m, 5H), 17.64 (s, 1H); Anal. Calcd. for C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>S: (%) C 57.13, H 4.13, N 13.33. Found: C 56.98, H 4.15, N 13.43.

*4-Hydroxy-3-methylthio-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-b]pyridin-6-one (4):* Pyrazole **3**<sup>19</sup> (1.5 g, 0.0048 mol) was added to H<sub>2</sub>SO<sub>4</sub> (90%, 6 ml) and heated at 130 °C for 20 min. The mixture was then added dropwise to an ice-water mixture (100 g), when **4** precipitated out as a white solid. The solid was filtered off and washed with ice-cold water to neutral and dried, m.p. 263–266 °C (dec.), yield 92 %; <sup>1</sup>H NMR δ (DMSO-d<sub>6</sub>, ppm): 2.60 (s, 3H), 4.05 (s, 2H), 5.87 (s, 1H), 7.18–8.16 (m, 5H); Anal. Calcd. for C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>S: C 57.14, H 4.03, N 15.38. Found: C 56.97, H 3.97, N 15.35 %.

*3-Methylthio-1-phenyl-5-phenylaminomethylene-1,7-dihydropyrazolo[3,4-b]pyridine-4,6-diones (5), general procedure:* Compound **4** (0.40 g, 0.0015 mol), triethyl orthoformate (0.67 g, 0.0045 mol), and a substituted aniline were refluxed in 10 ml ethanol and **5** precipitated out as a yellow solid in 5–10 min. The mixture was refluxed for 5 h and then cooled, and **5** was filtered off and recrystallised from DMF as yellow needles.

**5a:** m.p. >330 °C (dec.), yield 90 %; IR (KBr, cm<sup>-1</sup>): 3423, 3089, 2923, 2863, 1659, 1563, 1468, 1272, 845, 806, 768, 701; <sup>1</sup>H NMR δ (DMSO-d<sub>6</sub>, 70 °C, ppm): 2.32 (s, 3H), 2.50 (s, 3H), 7.24–7.57 (m, 9H), 8.64–8.72 (2d, 1H, *J* = 15 Hz), 11.20 (s, 1H), 12.22, 12.24 (dd, *J* = 15 Hz), 13.30, 13.5 (2d, *J* = 15 Hz); <sup>1</sup>H NMR δ (F<sub>3</sub>CCO<sub>2</sub>D, 70 °C, ppm): 2.31 (s, 3H), 2.70 (s, 3H), 7.27–7.67 (m, 9H), 8.90–9.10 (wide peak, 1H); MS *m/z*: 390 (M<sup>+</sup>), 313 (M-77)<sup>+</sup>, 299 (M-91)<sup>+</sup>, 284 (M-106)<sup>+</sup>, 73 (MeSCN)<sup>+</sup>, 44 (base peak); Anal. Calcd. for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S: C 64.61, H 4.65, N 14.35; Found: C 64.52, H 4.39, N 14.20 %.

*5-o-Chloroanilinomethyl derivative 5b:* m.p. >330 °C (dec.), yield 91 %; <sup>1</sup>H NMR δ (DMSO-d<sub>6</sub>, 70 °C, ppm): 2.49 (s, 3H), 7.20–7.80 (m, 9H), 8.80 (m, 1H), 11.20 (s, 1H), 12.80 (d, *J* = 12 Hz), 13.70 (dd, *J* = 12 Hz); <sup>1</sup>H NMR δ (F<sub>3</sub>CCO<sub>2</sub>D, 70 °C, ppm): 2.70 (s, 3H), 7.20–7.69 (m, 9H), 9.03, 9.23 (ds, 1H); Anal. Calcd. for C<sub>20</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>S: C 58.46, H 3.65, N13.64; Found: C 58.46, H 3.87, N 13.88 %.

*5-o-Bromoanilinomethyl derivative 5c:* m.p. >330 °C (dec.), yield 88 %; <sup>1</sup>H NMR δ (DMSO-d<sub>6</sub>, 70 °C, ppm): 2.51 (s, 3H), 7.19–7.94 (m, 9H), 8.76 (dd, 1H, *J* = 15 Hz), 12.80 (d, *J* = 12 Hz), 13.6 (d, *J* = 15 Hz); Anal. Calcd. for C<sub>20</sub>H<sub>15</sub>BrN<sub>4</sub>O<sub>2</sub>S: C 52.75, H 3.30, N 12.31; Found: C 52.62, H 3.19, N 12.41 %.

*5-o-Toluidinomethyl derivative 5d:* m.p. >330 °C(dec.), yield 92 %; <sup>1</sup>H NMR δ (DMSO-d<sub>6</sub>, 70 °C, ppm): 2.41 (s, 3H), 2.49 (s, 3H), 7.32–7.52 (m, 9H), 8.75 (dd, 1H, *J* = 12 Hz), 11.20 (s, 1H), 12.60 (d, *J* = 12 Hz), 13.60 (d, *J* = 15 Hz); Anal. Calcd. for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S: (%) C 64.62, H 4.62, N 14.35; Found: C 64.62, H 4.47, N 14.35.

The project is supported by the “863” program (2001AA235011).

Received 11 November 2002; accepted 13 September 2003  
Paper 02/1661

## References

- (a) M. Hisadome, T. Fukuda and M. Terasawa, *Int. J. Immunopharmacol.*, 1992, **14**, 1195; (b) H. Kobayashi and M. Kudame, JP 05 331 168 (1994) (*Chem. Abstr.*, **121**, 108 778r); (c) S.A. Lipton, WO 9 203 137 (1992) (*Chem. Abstr.*, **117**, 83 454j); (d) S. Christian, T. Aknad, M. Markus and M. Friedrich, DE 4 230 755 (1994) (*Chem. Abstr.*, **120**, 236 189r).
- (a) H. Takashi, T. Katushira, H. Yamaguchi, Y. Kawabata, H. Harayama, Y. Oda and M. Murai, WO 0006594 (1998) (*Chem. Abstr.* **132**, 151 835w); (b) A.A. Abdel Hafez, I.M.A. Awad and M.F. El-Zahry, *J. Chem. Technol. Biotechnol.*, 1992, **54**, 369.
- J.P. Stasch, E.M. Becker, C. Alonso-Alija, H. Apeler, K. Dembowski, A. Feurer, H. Schroder, W. Schroeder, E. Stahl, W. Steinke, A. Straub and M. Schramm, *Nature*, 2001, **410** (6825), 212.
- A. Straub, J. Benet-Buckholz, R. Frode, A. Kern, C. Kohlsdorfer, P. Schmitt, T. Schwarz, H.M. Siefert and J.P. Stasch, *Bioorg. Med. Chem.*, 2002, **10**, 1771.
- J.P. Stasch, A. Feurer, S. Weigand, E. Stahl, D. Flubacher, C. Alonso-Alija, F. Wunder, D. Lang, K. Debowski, A. Straub and E. Perzborn, *DE 10131987(23/5/2002)* (*Chem. Abstr.*, **136**, 401 774); *DE 10057754 (23/5/2002)* (*Chem. Abstr.*, **136**, 401 773); *DE 10057751 (23/5/2002)* (*Chem. Abstr.*, **136**, 401 772); *DE 10122895 (23/5/2002)* (*Chem. Abstr.*, **136**, 386 130).
- H. Kawasaki, K. Ozawa and K. Yamamoto, WO 2001 098 301 (27/12/2001) (*Chem. Abstr.*, **136**, 69807).
- S. Garland, D. Haigh, D.M.B. Hickey, J. Liddle, D.G. Smith, J. Witherington and R.W. Ward, WO 2002 024 694 (28/4/2002) (*Chem. Abstr.*, **136**, 263 167).
- C.M.S. Menezes, C.M.R. Sant'Anna, C.R. Rodrigues and E.J. Barreiro *J. Mol. Struct. - Theochem.*, 2002, **579**, 31.
- A.W. Erian, S. El-Gohary, F.M. Nmanhi and F.A. Ali, *Pharmazie*, 1998, **53**, 748.
- C. Neubing, D.W. Von, H. Theobald, K.O. Westphalen, U. Kardorff, H. Walter, T. Kappe and M. Gerber, DE 4 227 747 (1994) (*Chem. Abstr.*, **120**, 323 554).
- T. Ooe, H. Kabayashi, R. Ikezawa and M. Kudome, JP 06 206 872 (1994) (*Chem. Abstr.*, **122**, 187 576v).
- W.G. Zhao, Z.M. Li, and D.K. Yuan, *J. Chem. Research (S)*, 2002, 454.
- (a) A. Diaz-Ortiz, J.R. Carrillo, M.J. Gomez-Escalonilla, A. de la Hoz, A. Moreno and P. Prieto, *Synlett*, 1998, 10, 1069; (b) S. Rednekar and S. Gosavi, *Indian J. Heterocycl. Chem.* 1998, 8, 89; (c) R.N. Misra, S.D. Kimball, D.B. Rawlins, K.R. Webster and I. Bursuker, *WO 99 30 710* (1999) (*Chem. Abstr.*, **131**, 116 184r); (d) J. Quiroga, B. Insuasty, A. Hormaza, P. Cabildo and R.S. Claramut, *Heterocycl. Commun.* 1999, 5, 115; (e) J. Quiroga, M. Alvarado, B. Insuasty, R. Moreno, E. Ravina, I. Estevez and R.H. de Almeida, *J. Heterocycl. Chem.* 1999, 36, 1311; (f) T.L. El-Emary, A.M. Hussan and H.S. El-Kasshef, *Pharmazie* 2000, 55, 356; (g) J. Quiroga, S. Cruz, B. Insuasty and R. Abonia, *Heterocycl. Commun.* 2000, 6, 275. (h) J. Quiroga, S. Cruz, B. Insuasty, R. Abonia, J. Cobo, A. Sanchez, M. Nogueras and J. N. Low, *J. Heterocycl. Chem.*, 2001, 38, 53.
- J.C. Russell and D.O.H. Davids, *J. Chem. Soc., Perkin Trans. I*, 1991, 2537.
- M.T. Cocco, C. Congiu and V. Onnis, *Eur. J. Med. Chem.*, 2000, **35**, 545.
- Y.M. Wang, Z.M. Li and J.F. Li, *Chem. J. Chinese Universities*, 1999, **20**, 1559.
- (a) C.V. Augusto, C. Rosella and F.M. Caelo, *Tetrahedron*, 1995, **51**, 12 277; (b) J.N. Collie, *J. Chem. Soc.*, 1891, **59**, 609, 617.
- Y.M. Wang, K. He and G.F. Zhao, *Chinese Chem. Lett.*, 2003, **14**, 221.
- Y. Tominaga, Y. Honkawa, M. Hara and A. Hosomi, *J. Heterocyclic Chem.*, 1990, **27**, 775.